Alvotech
ALVOHealthcare|Drug Manufacturers - Specialty & Generic|LU
$4.86
+0.31 (+6.81%)
Cash / Share
$0.40
Clinical Trials (20)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07489131 Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema | Diabetic Macular Edema | P3 | Recruiting | 256 | RCT, Double-blind | AVT29 (proposed aflibercept HD biosimilar), Eylea HD (aflibercept HD) |
| NCT07475572 Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | Melanoma | P1 | Recruiting | 120 | RCT, Double-blind | AVT32-DRL_PB, Keytruda |
| NCT05395091 Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND | Osteoporosis, Postmenopausal | P3 | Completed | 532 | RCT, Double-blind | AVT03, Denosumab |
| NCT04930042 Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis | Psoriasis | P3 | Completed | 581 | RCT, Double-blind | Stelara, AVT04 |
| NCT05842213 Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX | Rheumatoid Arthritis | P3 | Completed | 502 | RCT, Double-blind | AVT05 (proposed biosimilar to golimumab), Simponi (Golimumab) |
| NCT03849404 Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis | Plaque Psoriasis | P3 | Completed | 413 | RCT, Double-blind | Adalimumab |
| NCT05986786 Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease | Chorioretinal Vascular Disease | P3 | Completed | 35 | Open-label | — |
| NCT05155293 Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) | Neovascular (Wet) AMD | P3 | Completed | 413 | RCT, Double-blind | AVT06 (proposed aflibercept biosimilar), Eylea® (Aflibercept) |
| NCT04453137 Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis | Plaque Psoriasis | P3 | Completed | 567 | RCT, Double-blind | Adalimumab originator, Adalimumab biosimilar |
| NCT06570772 Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio | Ulcerative Colitis | P3 | Terminated | 301 | RCT, Double-blind | AVT16, Vedolizumab |
| NCT04224194 Auto-injector Real Life Handling in Patients | RA | P3 | Completed | 107 | Open-label | — |
| NCT03579823 Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 24 | RCT, Single-blind | Adalimumab 100 MG/ML [Humira], AVT02 100MG/ML |
| NCT06732804 Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio | Healthy Male and Female Subjects | P1 | Completed | 385 | RCT, Double-blind | AVT80, Geographical region 1 Entyvio, Geographical region 2 Entyvio |
| NCT05126784 AVT03 With Prolia in Healthy Male Subjects | Healthy Male Subjects | P1 | Completed | 209 | RCT, Double-blind | AVT03, Prolia |
| NCT05876949 AVT03 With Xgeva in Healthy Male Subjects | This is a Phase I Study Conducted in Healthy Volunteers | P1 | Completed | 208 | RCT, Double-blind | AVT03, Denosumab |
| NCT06400719 Pilot Study of AVT16 in Healthy Adult Subjects | Healthy | P1 | Completed | 18 | Open-label | AVT16 |
| NCT05632211 A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants | Healthy Adult Subjects | P1 | Completed | 336 | RCT, Double-blind | AVT05, Simponi |
| NCT04744363 Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) | Psoriasis | P1 | Completed | 294 | RCT, Single-blind | Stelara PFS |
| NCT03849313 Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) | Healthy Volunteers | P1 | Completed | 390 | RCT, Double-blind | Adalimumab |
| NCT03983876 PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI) | Phase 1 | P1 | Completed | 207 | RCT, Open-label | Adalimumab |